| The cortisol stress response induced by surgery: A systematic review and meta‐analysis A Prete, Q Yan, K Al‐Tarrah, HK Akturk, LJ Prokop, F Alahdab, MA Foster, ... Clinical endocrinology 89 (5), 554-567, 2018 | 169 | 2018 |
| Multicenter trial of a tubeless, on-body automated insulin delivery system with customizable glycemic targets in pediatric and adult participants with type 1 diabetes SA Brown, GP Forlenza, BW Bode, JE Pinsker, CJ Levy, AB Criego, ... Diabetes Care 44 (7), 1630-1640, 2021 | 165 | 2021 |
| Immune checkpoint inhibitor‐induced type 1 diabetes: a systematic review and meta‐analysis HK Akturk, D Kahramangil, A Sarwal, L Hoffecker, MH Murad, AW Michels Diabetic Medicine 36 (9), 1075-1081, 2019 | 164 | 2019 |
| Adverse Events Associated with Immune Checkpoint Blockade HK Akturk, M Aaron W New England Journal of Medicine 378 (12), 1163-4, 2018 | 134* | 2018 |
| Alcohol consumption, diabetes risk, and cardiovascular disease within diabetes S Polsky, HK Akturk Current diabetes reports 17, 1-12, 2017 | 130 | 2017 |
| Pivotal evaluation of an artificial intelligence system for autonomous detection of referrable and vision-threatening diabetic retinopathy E Ipp, D Liljenquist, B Bode, VN Shah, S Silverstein, CD Regillo, JI Lim, ... JAMA network open 4 (11), e2134254-e2134254, 2021 | 109 | 2021 |
| Ever-increasing insulin-requiring patients globally SK Garg, AH Rewers, HK Akturk Diabetes technology & therapeutics 20 (S2), S2-1-S2-4, 2018 | 83 | 2018 |
| Long‐term real‐life glycaemic outcomes with a hybrid closed‐loop system compared with sensor‐augmented pump therapy in patients with type 1 diabetes HK Akturk, D Giordano, A Champakanath, S Brackett, S Garg, ... Diabetes, Obesity and Metabolism 22 (4), 583-589, 2020 | 78 | 2020 |
| Accuracy and safety of Dexcom G7 continuous glucose monitoring in adults with diabetes SK Garg, M Kipnes, K Castorino, TS Bailey, HK Akturk, JB Welsh, ... Diabetes technology & therapeutics 24 (6), 373-380, 2022 | 59 | 2022 |
| Evaluation of accuracy and safety of the next-generation up to 180-day long-term implantable eversense continuous glucose monitoring system: the PROMISE study SK Garg, D Liljenquist, B Bode, MP Christiansen, TS Bailey, RL Brazg, ... Diabetes Technology & Therapeutics 24 (2), 84-92, 2022 | 58 | 2022 |
| Inequity in racial-ethnic representation in randomized controlled trials of diabetes technologies in type 1 diabetes: critical need for new standards HK Akturk, S Agarwal, L Hoffecker, VN Shah Diabetes Care 44 (6), e121, 2021 | 54 | 2021 |
| Real-world evidence and glycemic improvement using Dexcom G6 features HK Akturk, R Dowd, K Shankar, M Derdzinski Diabetes technology & therapeutics 23 (S1), S-21-S-26, 2021 | 53 | 2021 |
| Diabetes mellitus and hypertension: a dual threat AA Oktay, HK Akturk, E Jahangir Current opinion in cardiology 31 (4), 402-409, 2016 | 53 | 2016 |
| Flash glucose monitoring: the future is here SK Garg, HK Akturk Diabetes Technology & Therapeutics 19 (S2), S-1-S-3, 2017 | 48 | 2017 |
| Improved postprandial glucose with inhaled technosphere insulin compared with insulin aspart in patients with type 1 diabetes on multiple daily injections: the STAT study HK Akturk, JK Snell-Bergeon, A Rewers, LJ Klaff, BW Bode, AL Peters, ... Diabetes Technology & Therapeutics 20 (10), 639-647, 2018 | 46 | 2018 |
| Continuous glucose monitoring initiation within first year of type 1 diabetes diagnosis is associated with improved glycemic outcomes: 7-year follow-up study A Champakanath, HK Akturk, GT Alonso, JK Snell-Bergeon, VN Shah Diabetes Care 45 (3), 750-753, 2022 | 42 | 2022 |
| Association between cannabis use and risk for diabetic ketoacidosis in adults with type 1 diabetes HK Akturk, DD Taylor, UM Camsari, A Rewers, GL Kinney, VN Shah JAMA internal medicine 179 (1), 115-118, 2019 | 42 | 2019 |
| Cannabis use is associated with increased risk for diabetic ketoacidosis in adults with type 1 diabetes: findings from the T1D exchange clinic registry GL Kinney, HK Akturk, DD Taylor, NC Foster, VN Shah Diabetes Care 43 (1), 247-249, 2020 | 40 | 2020 |
| PD-1 inhibitor immune-related adverse events in patients with preexisting endocrine autoimmunity HK Akturk, A Alkanani, Z Zhao, L Yu, AW Michels The Journal of Clinical Endocrinology & Metabolism 103 (10), 3589-3592, 2018 | 38 | 2018 |
| Real‐world performance of hybrid closed loop in youth, young adults, adults and older adults with type 1 diabetes: identifying a clinical target for hybrid closed‐loop use C Berget, HK Akturk, LH Messer, T Vigers, L Pyle, J Snell‐Bergeon, ... Diabetes, Obesity and Metabolism 23 (9), 2048-2057, 2021 | 37 | 2021 |
